ADA trims kid A1C levels

Share this article:
ADA trims kid A1C levels
ADA trims kid A1C levels

The American Diabetes Association is lowering the A1C ceiling for type 1 diabetes patients ages 18 and younger from 8.5% to 7.5%. The research organization announced the change Monday at the group's Scientific Sessions, the same day it published the supporting position statement in Diabetes Care.

The decision means the ADA's recommendations will fall in line with those of the International Society for Pediatric and Adolescent Diabetes, the Pediatric Endocrine Society and the International Diabetes Federation.

Until now the ADA allowed for variable glucose levels in which patients under the age of six could go as high as 8.5%, children between the ages of six and 12 could be 8.0%, and adolescents 7.5%.

Researchers said the previous guidelines “arose from a combination of two lines of unsubstantiated evidence,”  which predated innovations like insulin analogs and easily used glucometers. They write that the thinking at the time was that severe recurrent hypoglycemia accompanied by seizures or coma could have long-term consequences on brain development, but that high-ish glucose levels would not have long-term health consequences as long as they predated puberty.

Researchers note that recent studies show otherwise, and have failed to link neurocognitive decline with hypoglycemia among young children. Instead they report quite the opposite—that elevated glucose levels may “produce adverse outcomes in the short term on neurocognitive function.” They also note clinicians are increasingly thinking that keeping a lid on glucose levels before puberty may “reduce the risk for both micro- and macrovasular complications” later on.

Type 1 diabetes is associated with an increased risk for immunologic disorder celiac disease, and over- or under-active thyroids.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...